Showing 261 - 280 results of 2,171 for search 'Who's Who in the World', query time: 0.11s Refine Results
  1. 261
  2. 262
  3. 263
  4. 264

    A Real World Report on Intravenous High-Dose and Non-High-Dose Proton-Pump Inhibitors Therapy in Patients with Endoscopically Treated High-Risk Peptic Ulcer Bleeding by Lung-Sheng Lu, Sheng-Chieh Lin, Chung-Mou Kuo, Wei-Chen Tai, Po-Lin Tseng, Kuo-Chin Chang, Chung-Huang Kuo, Seng-Kee Chuah

    Published 2012-01-01
    “…This study aimed to understand the real world experiences in prescribing high-dose PPI and non-high-dose PPI for preventing rebleeding after endoscopic treatment of high-risk PU. …”
    Get full text
    Article
  5. 265
  6. 266

    Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analys... by Gregory Y H Lip, Sally Lee, Brigitta U Monz, Andreas Clemens, Martina Brueckmann

    Published 2012-12-01
    “…This study aimed to assess the representativeness for the real-world AF population, particularly the population eligible for anticoagulants.Design A cross-sectional database analysis.Setting Dataset derived from the General Practice Research Database (GPRD).Primary and secondary outcomes measure The proportion of real-world patients with AF who met the inclusion/exclusion criteria for RE-LY, ARISTOTLE and ROCKET-AF were compared. …”
    Get full text
    Article
  7. 267
  8. 268
  9. 269

    Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inh... by Lara Chayab, Natasha B. Leighl, Mina Tadrous, Christine M. Warren, William W. L. Wong

    Published 2024-12-01
    “…There was no significant difference in first-line OS between the treatment groups. In patients who received more than one line of treatment, there was a significant difference in mOS between patients who received two or more lines of ALK TKIs compared to those who received one line of ALK TKI (mOS = 55 months (95% CI, 400–987 days) and 26 months (95% CI, 1448–2644 days), respectively, HR = 4.64, <i>p</i> < 0.0001). …”
    Get full text
    Article
  10. 270

    Political Meanings, Identity Theory and the History of Ideas: Introducing the Issue by Daria B. Kazarinova, Aleksandr A. Shirinyants

    Published 2024-12-01
    “…The issue of the journal is devoted to a wide range of issues related to the history of ideas, identity issues, the multipolarity of the world, as well as the translation of value meanings and socio-cultural divisions. …”
    Get full text
    Article
  11. 271

    Deep patch‐wise supervision for presentation attack detection by Alperen Kantarcı, Hasan Dertli, Hazım Kemal Ekenel

    Published 2022-09-01
    “…The authors extensively tested the proposed method on widely used PAD data sets—Replay‐Mobile and OULU‐NPU—and on a real‐world data set that has been collected for real‐world PAD use cases. …”
    Get full text
    Article
  12. 272

    Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations by Jason C.S. Ho, K.M. Cheung

    Published 2024-01-01
    “…Among the 123 patients who underwent definitive chemoradiation, 33 had common driver mutations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and RET fusions. …”
    Get full text
    Article
  13. 273
  14. 274

    Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizu... by L. Johnetta Blakely, Sabine Oskar, Ian Kudel, Ashley Roush, Zoya Shamsi, Toni Perry, Annette Christianson, Brittni Smith, Thomas Burke

    Published 2025-01-01
    “…Methods: Adults with advanced NSCLC, ECOG performance status of 0–2, who received first-line (1L) pembrolizumab (monotherapy or with chemotherapy) were eligible. …”
    Article
  15. 275
  16. 276

    Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational stud... by Urpo Kiiskinen, Grace Segall, Hollie Bailey, Cameron Forshaw, Tarun Puri

    Published 2025-02-01
    “…IntroductionApproximately 1−2% of non-small cell lung cancers (NSCLCs) are positive for rearranged during transfection (RET) gene fusions. The aim of this real-world multi-national study was to describe clinical characteristics, biomarker testing, and treatment patterns of patients with RET fusion-positive NSCLC.MethodsThis observational study was conducted in 2020 in nine countries using electronic patient record forms, following Adelphi Disease Specific Programme (DSP™) methodology. …”
    Get full text
    Article
  17. 277

    Turkmen Students at Volgograd State Technical University by L. F. Belyakova, T. L. Sidorova, R. M. Petruneva, V. D. Vasilyeva

    Published 2020-05-01
    “…The attractiveness of the University in the world market of educational services is an indicator of its success, which is estimated by a set of criteria including the number of foreign students studying there. …”
    Get full text
    Article
  18. 278
  19. 279

    Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice by Marwa Al‐Badri, Shilton Dhaver, Osama Hamdy

    Published 2025-01-01
    “…Methods We retrospectively evaluated 256 patients with T2D who were treated with exenatide (n = 84), dulaglutide (n = 99), or semaglutide (n = 73) for 2.5 years without interruption in real‐world clinical practice. …”
    Get full text
    Article
  20. 280